This morning investors are almost certainly going to look into stocks that managed to record significant gains this past Friday and one of the stocks that could be tracked is that of Clovis Oncology (NASDAQ: CLVS).
The biopharmaceutical firm saw its stock soar by as high as 48% on Friday after the company provided positive updates from the Phase 3 study of its product Rubraca. The product in question is meant for treating patients suffering from ovarian cancer.
Data from the trial showed that Rubraca managed to improve progression-free survival (PFS) to a significant degree and that was one of the major reasons behind the excitement about the stock. The Phase 3 study had been performed on as many as 349 patients spread across many countries and represents a major milestone for Clovis Oncology. It now remains to be seen if the positive update and the gains on Friday can give the stock further momentum this week.
Editor and Computer Expert
A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.